Converging pathways in the occurrence of endoplasmic reticulum (er) stress in Huntington's disease

Current Molecular Medicine

Volumn 11, Issue 1, 2011, Pages 1-12

  Vidal, R ^a,b   Caballero, B ^a,b   Couve, A ^b   Hetz, C ^a,b,c,d  

^a UNIVERSITY OF CHILE   (Chile)

^b UNIVERSITY OF CHILE   (Chile)

^c Neurounion Biomedical Foundation   (Chile)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Endoplasmic reticulum; ER stress; Huntingtin; Huntington's disease; Protein misfolding; Unfolded protein response

Indexed keywords

HUNTINGTIN; MUTANT PROTEIN;

APOPTOSIS; CALCIUM HOMEOSTASIS; CELL MIGRATION; CLINICAL FEATURE; ENDOPLASMIC RETICULUM STRESS; GENE MUTATION; GOLGI COMPLEX; HUMAN; HUNTINGTON CHOREA; NERVE FIBER TRANSPORT; NONHUMAN; PROTEIN DEGRADATION; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROCESSING; REVIEW;

ANIMALS; APOPTOSIS; CALCIUM; ENDOPLASMIC RETICULUM; HUMANS; HUNTINGTON DISEASE; NERVE TISSUE PROTEINS; NUCLEAR PROTEINS; PROTEIN MULTIMERIZATION; PROTEIN TRANSPORT; PROTEOSTASIS DEFICIENCIES; STRESS, PHYSIOLOGICAL; UNFOLDED PROTEIN RESPONSE;

EID: 78650827764     PISSN: 15665240     EISSN: None     Source Type: Journal    
DOI: 10.2174/156652411794474419     Document Type: Review

References (137)

1. Dellen Av, Grote HE, Hannan AJ. Gene environmentinteractions, neuronal dysfuntion and pathological plasticity in Huntington's diseases. Clin Exp Pharmacol Physiol 2005 32: 1007-19.
2. Cattaneo E, Zuccato C, Tartari M. Normal huntingtin function:an alternative approach to Huntington's disease. Nat Rev Neurosci 2005; 6: 919-30.
3. Rockabrand E, Slepko N, Pantalone A, et al. The first 17amino acids of Huntingtin modulate its sub-cellularlocalization, aggregation and effects on calciumhomeostasis. Hum Mol Genet 2007; 16: 61-77.
4. Pennuto M, Palazzolo I, Poletti A. Post-translationalmodifications of expanded polyglutamine proteins: impact onneurotoxicity. Hum Mol Genet 2009; 18: R40-7.
5. Longshore JW, Tarleton J. Dynamic mutations in humangenes: a review of trinucleotide repeat disease. J Genet 1996; 75: 193-217.
6. Kremer B, Goldberg P, Andrew SE, et al. A worldwide studyof the Huntington's disease mutation. The sensitivity andspecificity of measuring CAG repeats. N Engl J Med 1994; 330: 1401-6.
7. Heng MY, Detloff PJ, Albin RL. Rodent genetic models of Huntington disease. Neurobiol Dis 2008; 32: 1-9.
8. Kalchman MA, Graham RK, Xia G, et al. Huntingtin isubiquitinated and interacts with a specific ubiquitinconjugatingenzyme. J Biol Chem 1996; 271: 19385-94.
9. Sieradzan KA, Mechan AO, Jones L, et al. Huntington'sdisease intranuclear inclusions contain truncated, ubiquitinated huntingtin protein. Exp Neurol 1999; 156: 92-9.
10. Bence NF, Sampat RM, Kopito RR. Impairment of theubiquitin-proteasome system by protein aggregation. Science 2001; 292: 1552-5.
11. Shao J, Diamond MI. Polyglutamine diseases: emergingconcepts in pathogenesis and therapy. Hum Mol Genet 2007; 16 Spec No. 2: R 115-23.
12. Hoffner G, Soues S, Djian P. Aggregation of expandedhuntingtin in the brains of patients with Huntington disease. Prion 2007; 1: 26-31.
13. Imarisio S, Carmichael J, Korolchuk V, et al. Huntington'sdisease: from pathology and genetics to potential therapies. Biochem J 2008; 412: 191-209.
14. Heng MY, Detloff PJ, Wang PL, Tsien JZ, Albin RL. In vivoevidence for NMDA receptor-mediated excitotoxicity in amurine genetic model of Huntington disease. J Neurosci 2009; 29: 3200-5.
15. Dellen Av, Grote HE, Hannan AJ. Gene environmentinteractions, neuronal dysfuntion and pathological plasticity in Huntington's diseases. Clin Exp Pharmacol Physiol 2005 32: 1007-19.
16. Cattaneo E, Zuccato C, Tartari M. Normal huntingtin function:an alternative approach to Huntington's disease. Nat Rev Neurosci 2005; 6: 919-30.
17. Rockabrand E, Slepko N, Pantalone A, et al. The first 17amino acids of Huntingtin modulate its sub-cellularlocalization, aggregation and effects on calciumhomeostasis. Hum Mol Genet 2007; 16: 61-77.
18. Pennuto M, Palazzolo I, Poletti A. Post-translationalmodifications of expanded polyglutamine proteins: impact onneurotoxicity. Hum Mol Genet 2009; 18: R40-7.
19. Longshore JW, Tarleton J. Dynamic mutations in humangenes: a review of trinucleotide repeat disease. J Genet 1996; 75: 193-217.
20. Kremer B, Goldberg P, Andrew SE, et al. A worldwide studyof the Huntington's disease mutation. The sensitivity andspecificity of measuring CAG repeats. N Engl J Med 1994; 330: 1401-6.
21. Heng MY, Detloff PJ, Albin RL. Rodent genetic models of Huntington disease. Neurobiol Dis 2008; 32: 1-9.
22. Kalchman MA, Graham RK, Xia G, et al. Huntingtin isubiquitinated and interacts with a specific ubiquitinconjugatingenzyme. J Biol Chem 1996; 271: 19385-94.
23. Sieradzan KA, Mechan AO, Jones L, et al. Huntington'sdisease intranuclear inclusions contain truncated, ubiquitinated huntingtin protein. Exp Neurol 1999; 156: 92-9.
24. Bence NF, Sampat RM, Kopito RR. Impairment of theubiquitin-proteasome system by protein aggregation. Science 2001; 292: 1552-5.
25. Shao J, Diamond MI. Polyglutamine diseases: emergingconcepts in pathogenesis and therapy. Hum Mol Genet 2007; 16 Spec No. 2: R 115-23.
26. Hoffner G, Soues S, Djian P. Aggregation of expandedhuntingtin in the brains of patients with Huntington disease. Prion 2007; 1: 26-31.
27. Imarisio S, Carmichael J, Korolchuk V, et al. Huntington'sdisease: from pathology and genetics to potential therapies. Biochem J 2008; 412: 191-209.
28. Heng MY, Detloff PJ, Wang PL, Tsien JZ, Albin RL. In vivoevidence for NMDA receptor-mediated excitotoxicity in amurine genetic model of Huntington disease. J Neurosci 2009; 29: 3200-5.
29. Estrada-Sánchez AM, Montiel T, Segovia J, Massieu L. Glutamate toxicity in the striatum of the R6/2 Huntington'sdisease transgenic mice is age-dependent and correlateswith decreased levels of glutamate transporters. Neurobiol Dis 2009; 34: 78-86.
30. Levine MS, Cepeda C, Andre VM. Location, location, location: contrasting roles of synaptic and extrasynapticNMDA receptors in Huntington's disease. Neuron 2010; 65: 145-7.
31. Bossy-Wetzel E, Petrilli A, Knott AB. Mutant huntingtin andmitochondrial dysfunction. Trends Neurosci 2008; 31: 609-16.
32. Browne SE. Mitochondria and Huntington's diseasepathogenesis: insight from genetic and chemical models. Ann N Y Acad Sci 2008; 1147: 358-82.
33. Quintanilla RA, Johnson GV. Role of mitochondrialdysfunction in the pathogenesis of Huntington's disease. Brain Res Bull 2009; 80: 242-7.
34. Damiano M, Galvan L, Deglon N, Brouillet E. Mitochondria in Huntington's disease. Biochim Biophys Acta 2010; 1802: 52-61.
35. Browne SE, Beal MF. Oxidative damage in Huntington'sdisease pathogenesis. Antioxid Redox Signal 2006; 8: 2061-73.
36. Becanovic K, Pouladi M, Lim RS, et al. Transcriptionalchanges in Huntington Disease identified using genome-wideexpression profiling and cross platform analysis. Hum Mol Genet 2010; 19: 1438-52.
37. Mazarei G, Neal SJ, Becanovic K, et al. Expression analysisof novel striatal-enriched genes in Huntington disease. Hum Mol Genet 2010; 19: 609-22.
38. Cha J-HJ. Transcriptional signatures in Huntington's disease. Prog Neurobiol 2007; 83: 228-48.
39. Borovecki F, Lovrecic L, Zhou J, et al. Genome-wideexpression profiling of human blood reveals biomarkers for Huntington's disease. Proc Natl Acad Sci USA 2005; 102: 11023-8.
40. Bithell A, Johnson R, Buckley NJ. Transcriptionaldysregulation of coding and non-coding genes in cellularmodels of Huntington's disease. Biochem Soc Trans 2009; 37: 1270-5.
41. Bhattacharyya NP, Banerjee M, Majumder P. Huntington'sdisease: roles of huntingtin-interacting protein 1 (HIP-1) andits molecular partner HIPPI in the regulation of apoptosis andtranscription. FEBS J 2008; 275: 4271-9.
42. Bett JS, Goellner GM, Woodman B, et al. Proteasomeimpairment does not contribute to pathogenesis in R6/2Huntington's disease mice: exclusion of proteasome activatorREGgamma as a therapeutic target. Hum Mol Genet 2006; 15: 33-44.
43. Maynard CJ, Bottcher C, Ortega Z, et al. Accumulation ofubiquitin conjugates in a polyglutamine disease model occurswithout global ubiquitin/proteasome system impairment. Proc Natl Acad Sci USA 2009; 106: 13986-91.
44. Paul S. Dysfunction of the ubiquitin-proteasome system inmultiple disease conditions: therapeutic approaches. Bioessays 2008; 30: 1172-84.
45. Trushina E, Dyer RB, Badger JD, 2nd, et al. Mutanthuntingtin impairs axonal trafficking in mammalian neurons invivo and in vitro. Mol Cell Biol 2004; 24: 8195-209.
46. Schweitzer JK, Krivda JP, D'Souza-Schorey C. Neurodegeneration in Niemann-Pick Type C disease and Huntington's disease: impact of defects in membranetrafficking. Curr Drug Targets 2009; 10: 653-65.
47. De Vos KJ, Grierson AJ, Ackerley S, Miller CC. Role ofaxonal transport in neurodegenerative diseases. Annu Rev Neurosci 2008; 31: 151-73.
48. Gunawardena S, Goldstein LS. Polyglutamine diseases andtransport problems: deadly traffic jams on neuronalhighways. Arch Neurol 2005; 62: 46-51.
49. Matus S, Lisbona F, Torres M, et al. The stress rheostat: aninterplay between the unfolded protein response (UPR) andautophagy in neurodegeneration. Curr Mol Med 2008; 8: 157-72.
50. Hetz C, Glimcher LH. Fine-tuning of the unfolded proteinresponse: Assembling the IRE1alpha interactome. Mol Cell 2009; 35: 551-61.
51. Harding HP, Zhang Y, Ron D. Protein translation and foldingare coupled by an endoplasmic-reticulum-resident kinase. Nature 1999; 397: 271-4.
52. Ron D, Walter P. Signal integration in the endoplasmicreticulum unfolded protein response. Nat Rev Mol Cell Biol 2007; 8: 519-29.
53. Schroder M, Kaufman RJ. The mammalian unfolded proteinresponse. Annu Rev Biochem 2005; 74: 739-89.
54. Rutkowski DT, Arnold SM, Miller CN, et al. Adaptation to ERstress is mediated by differential stabilities of pro-survivaland pro-apoptotic mRNAs and proteins. PLoS Biol 2006; 4:e374.
55. Calfon M, Zeng H, Urano F, et al. IRE1 couples endoplasmicreticulum load to secretory capacity by processing the XBP-1mRNA. Nature 2002; 415: 92-6.
56. Lee K, Tirasophon W, Shen X, et al. IRE1-mediatedunconventional mRNA splicing and S2P-mediated ATF6cleavage merge to regulate XBP1 in signaling the unfoldedprotein response. Genes Dev 2002; 16: 452-66.
57. Yoshida H, Matsui T, Yamamoto A, Okada T, Mori K. XBP1mRNA is induced by ATF6 and spliced by IRE1 in responseto ER stress to produce a highly active transcription factor. Cell 2001; 107: 881-91.
58. Chen X, Shen J, Prywes R. The luminal domain of ATF6senses endoplasmic reticulum (ER) stress and causestranslocation of ATF6 from the ER to the Golgi. J Biol Chem 2002; 277: 13045-52.
59. Haze K, Yoshida H, Yanagi H, Yura T, Mori K. Mammaliantranscription factor ATF6 is synthesized as a transmembraneprotein and activated by proteolysis in response toendoplasmic reticulum stress. Mol Biol Cell 1999; 10: 3787-99.
60. Lee AH, Iwakoshi NN, Glimcher LH. XBP-1 regulates asubset of endoplasmic reticulum resident chaperone genesin the unfolded protein response. Mol Cell Biol 2003; 23: 7448-59.
61. Nishitoh H, Matsuzawa A, Tobiume K, et al. ASK1 isessential for endoplasmic reticulum stress-induced neuronalcell death triggered by expanded polyglutamine repeats. Genes Dev 2002; 16: 1345-55.
62. Urano F, Wang X, Bertolotti A, et al. Coupling of stress in the ER to activation of JNK protein kinases by transmembraneprotein kinase IRE1. Science 2000; 287: 664-6.
63. Kim I, Shu CW, Xu W, et al. Chemical biology investigation ofcell death pathways activated by endoplasmic reticulumstress reveals cytoprotective modulators of ASK1. J Biol Chem 2009; 284: 1593-603.
64. Hetz C, Bernasconi P, Fisher J, et al. Proapoptotic BAX and BAK modulate the unfolded protein response by a directinteraction with IRE1alpha. Science 2006; 312: 572-6.
65. Lisbona F, Rojas-Rivera D, Thielen P, et al. BAX inhibitor-1is a negative regulator of the ER stress sensor IRE1alpha. Mol Cell 2009; 33: 679-91.
66. Rojas-Rivera D, Caballero B, Zamorano S, Lisbona F, Hetz C. Alternative functions of the BCL-2 protein family at theendoplasmic reticulum. Adv Exp Med Biol 2010; 687: 33-47.
67. Danial NN, Korsmeyer SJ. Cell death: critical control points. Cell 2004; 116: 205-19.
68. Youle RJ, Strasser A. The BCL-2 protein family: opposingactivities that mediate cell death. Nat Rev Mol Cell Biol 2008; 9: 47-59.
69. Li J, Lee B, Lee AS. Endoplasmic reticulum stress-inducedapoptosis: multiple pathways and activation of p53-upregulatedmodulator of apoptosis (PUMA) and NOXA by p53. J Biol Chem 2006; 281: 7260-70.
70. Reimertz C, Kogel D, Rami A, Chittenden T, Prehn JH. Geneexpression during ER stress-induced apoptosis in neurons:induction of the BH3-only protein Bbc3/PUMA and activationof the mitochondrial apoptosis pathway. J Cell Biol 2003; 162: 587-97.
71. Li L, Murphy TH, Hayden MR, Raymond LA. Enhancedstriatal NR2B-containing N-methyl-D-aspartate receptormediatedsynaptic currents in a mouse model of Huntingtondisease. J Neurophysiol 2004; 92: 2738-46.
72. Fan MM, Fernandes HB, Zhang LY, Hayden MR, Raymond LA. Altered NMDA receptor trafficking in a yeast artificialchromosome transgenic mouse model of Huntington'sdisease. J Neurosci 2007; 27: 3768-79.
73. Twelvetrees AE, Yuen EY, Arancibia-Carcamo IL, et al. Delivery of GABAARs to synapses is mediated by HAP1-KIF5 and disrupted by mutant huntingtin. Neuron 2010; 65: 53-65.
74. Gauthier LR, Charrin BC, Borrell-Pages M, et al. Huntingtincontrols neurotrophic support and survival of neurons byenhancing BDNF vesicular transport along microtubules. Cell 2004; 118: 127-38.
75. Li XJ, Li SH. HAP1 and intracellular trafficking. Trends Pharmacol Sci 2005; 26: 1-3.
76. McGuire JR, Rong J, Li SH, Li XJ. Interaction of Huntingtinassociatedprotein-1 with kinesin light chain: implications inintracellular trafficking in neurons. J Biol Chem 2006; 281: 3552-9.
77. Kittler JT, Thomas P, Tretter V, et al. Huntingtin-associatedprotein 1 regulates inhibitory synaptic transmission bymodulating gamma-aminobutyric acid type A receptormembrane trafficking. Proc Natl Acad Sci USA 2004; 101: 12736-41.
78. Ravikumar B, Imarisio S, Sarkar S, O'Kane CJ, Rubinsztein DC. Rab5 modulates aggregation and toxicity of mutanthuntingtin through macroautophagy in cell and fly models of Huntington disease. J Cell Sci 2008; 121: 1649-60.
79. Metzler M, Li B, Gan L, et al. Disruption of the endocyticprotein HIP1 results in neurological deficits and decreasedAMPA receptor trafficking. EMBO J 2003; 22: 3254-66.
80. Metzler M, Gan L, Wong TP, et al. NMDA receptor functionand NMDA receptor-dependent phosphorylation of huntingtinis altered by the endocytic protein HIP1. J Neurosci 2007; 27: 2298-308.
81. Sapp E, Penney J, Young A, et al. Axonal transport of Nterminalhuntingtin suggests early pathology of corticostriatalprojections in Huntington disease. J Neuropathol Exp Neurol 1999; 58: 165-73.
82. Di Figlia M, Sapp E, Chase KO, et al. Aggregation ofhuntingtin in neuronal intranuclear inclusions and dystrophicneurites in brain. Science 1997; 277: 1990-3.
83. Duncan JE, Goldstein LS. The genetics of axonal transportand axonal transport disorders. PLoS Genet 2006; 2: e124.
84. Gunawardena S, Her LS, Brusch RG, et al. Disruption ofaxonal transport by loss of huntingtin or expression ofpathogenic polyQ proteins in Drosophila. Neuron 2003; 40: 25-40.
85. Szebenyi G, Morfini GA, Babcock A, et al. Neuropathogenicforms of huntingtin and androgen receptor inhibit fast axonaltransport. Neuron 2003; 40: 41-52.
86. Lee WC, Yoshihara M, Littleton JT. Cytoplasmic aggregatestrap polyglutamine-containing proteins and block axonaltransport in a Drosophila model of Huntington's disease. Proc Natl Acad Sci USA 2004; 101: 3224-9.
87. Chang DT, Rintoul GL, Pandipati S, Reynolds IJ. Mutanthuntingtin aggregates impair mitochondrial movement andtrafficking in cortical neurons. Neurobiol Dis 2006; 22: 388-400.
88. Orr AL, Li S, Wang CE, et al. N-terminal mutant huntingtinassociates with mitochondria and impairs mitochondrialtrafficking. J Neurosci 2008; 28: 2783-92.
89. Di Figlia M, Sapp E, Chase K, et al. Huntingtin is acytoplasmic protein associated with vesicles in human andrat brain neurons. Neuron 1995; 14: 1075-81.
90. Bhide PG, Day M, Sapp E, et al. Expression of normal andmutant huntingtin in the developing brain. J Neurosci 1996; 16: 5523-35.
91. Velier J, Kim M, Schwarz C, et al. Wild-type and mutanthuntingtins function in vesicle trafficking in the secretory andendocytic pathways. Exp Neurol 1998; 152: 34-40.
92. Li H, Wyman T, Yu ZX, Li SH, Li XJ. Abnormal association ofmutant huntingtin with synaptic vesicles inhibits glutamaterelease. Hum Mol Genet 2003; 12: 2021-30.
93. Block-Galarza J, Chase KO, Sapp E, et al. Fast transportand retrograde movement of huntingtin and HAP 1 in axons. Neuroreport 1997; 8: 2247-51.
94. Her LS, Goldstein LS. Enhanced sensitivity of striatalneurons to axonal transport defects induced by mutanthuntingtin. J Neurosci 2008; 28: 13662-72.
95. Engelender S, Sharp AH, Colomer V, et al. Huntingtinassociatedprotein 1 (HAP1) interacts with the p 150Gluedsubunit of dynactin. Hum Mol Genet 1997; 6: 2205-12.
96. Li SH, Gutekunst CA, Hersch SM, Li XJ. Interaction ofhuntingtin-associated protein with dynactin P 150Glued. JNeurosci 1998; 18: 1261-9.
97. Caviston JP, Ross JL, Antony SM, Tokito M, Holzbaur EL. Huntingtin facilitates dynein/dynactin-mediated vesicletransport. Proc Natl Acad Sci US A 2007; 104: 10045-50.
98. Morfini GA, You YM, Pollema SL, et al. Pathogenic huntingtininhibits fast axonal transport by activating JNK3 andphosphorylating kinesin. Nat Neurosci 2009; 12: 864-71.
99. Levine B, Deretic V. Unveiling the roles of autophagy ininnate and adaptive immunity. Nat Rev Immunol 2007; 7: 767-77.
100. Levine B, Kroemer G. Autophagy in the pathogenesis ofdisease. Cell 2008; 132: 27-42.
101. Mizushima N, Levine B, Cuervo AM, Klionsky DJ. Autophagyfights disease through cellular self-digestion. Nature 2008; 451: 1069-75.
102. Yang L, Li P, Fu S, Calay ES, Hotamisligil GS. Defectivehepatic autophagy in obesity promotes ER stress and causesinsulin resistance. Cell Metab 2010; 11: 467-78.
103. He C, Klionsky DJ. Regulation Mechanisms and Signaling Pathways of Autophagy. Annu Rev Genet 2009; 43: 67-93.
104. Naiki H, Nagai Y. Molecular Pathogenesis of proteinmisfolding diseases: pathological molecular environmentsversus quality control systems against misfolded proteins. J Biochem 2009; 146 751-6.
105. Shibata M, Lu T, Furuya T, et al. Regulation of intracellularaccumulation of mutant Huntingtin by Beclin 1. J Biol Chem 2006; 281: 14474-85.
106. Martinez-Vicente M, Talloczy Z, Wong E, et al. Cargorecognition failure is responsible for inefficient autophagy in Huntington's disease. Nat Neurosci 2010; 13: 567-76.
107. Zheng S, Clabough EB, Sarkar S, et al. Deletion of thehuntingtin polyglutamine stretch enhances neuronalautophagy and longevity in mice. PLoS Genet 2010; 6:e1000838.
108. Bernales S, Schuck S, Walter P. ER-phagy: selectiveautophagy of the endoplasmic reticulum. Autophagy 2007; 3: 285-7.
109. Gorlach A, Klappa P, Kietzmann T. The endoplasmicreticulum: folding, calcium homeostasis, signaling, and redoxcontrol. Antioxid Redox Signal 2006; 8: 1391-418.
110. Michalak M, Robert Parker JM, Opas M. Ca2+ signaling andcalcium binding chaperones of the endoplasmic reticulum. Cell Calcium 2002; 32: 269-78.
111. Berridge MJ. The endoplasmic reticulum: a multifunctionalsignaling organelle. Cell Calcium 2002; 32: 235-49.
112. Pinton P, Rizzuto R. Bcl-2 and Ca2+ homeostasis in theendoplasmic reticulum. Cell Death Differ 2006; 13: 1409-18.
113. Varshney A, Ehrlich BE. Intracellular Ca2+ signaling andhuman disease: the hunt begins with Huntington's. Neuron 2003; 39: 195-7.
114. Diaz-Hernandez M, Diez-Zaera M, Sanchez-Nogueiro J, etal. Altered P2X7-receptor level and function in mouse modelsof Huntington's disease and therapeutic efficacy ofantagonist administration. FASEB J 2009; 23: 1893-906.
115. Zhang H, Li Q, Graham RK, et al. Full length mutanthuntingtin is required for altered Ca2+ signaling andapoptosis of striatal neurons in the YAC mouse model of Huntington's disease. Neurobiol Dis 2008; 31: 80-8.
116. Tang TS, Slow E, Lupu V, et al. Disturbed Ca2+ signalingand apoptosis of medium spiny neurons in Huntington'sdisease. Proc Natl Acad Sci USA 2005; 102: 2602-7.
117. Tang TS, Tu H, Chan EY, et al. Huntingtin and huntingtinassociatedprotein 1 influence neuronal calcium signalingmediated by inositol-(1,4,5) triphosphate receptor type 1. Neuron 2003; 39: 227-39.
118. Bezprozvanny I, Hayden MR. Deranged neuronal calciumsignaling and Huntington disease. Biochem Biophys Res Commun 2004; 322: 1310-7.
119. Bezprozvanny I. Inositol 1,4,5-tripshosphate receptor, calcium signalling and Huntington's disease. Subcell Biochem 2007; 45: 323-35.
120. Ong DS, Mu TW, Palmer AE, Kelly JW. Endoplasmicreticulum Ca2+ increases enhance mutantglucocerebrosidase proteostasis. Nat Chem Biol 2010; 6: 424-32.
121. Humbert S, Saudou F. Toward cell specificity in SCA1. Neuron 2002; 34: 669-70.
122. Rigamonti D, Mutti C, Zuccato C, Cattaneo E, Contini A. Turning REST/NRSF dysfunction in Huntington's disease intoa pharmaceutical target. Curr Pharm Des 2009; 15: 3958-67.
123. Fernandez-Fernandez MR, Ferrer I, Lucas JJ. Impaired ATF6alpha processing, decreased Rheb and neuronal cellcycle re-entry in Huntington's disease. Neurobiol Dis 2010.
124. Gkogkas C, Middleton S, Kremer AM, et al. VAPB interactswith and modulates the activity of ATF6. Hum Mol Genet 2008; 17: 1517-26.
125. Vedrenne C, Hauri HP. Morphogenesis of the endoplasmicreticulum: beyond active membrane expansion. Traffic 2006; 7: 639-46.
126. Ferrante RJ, Kubilus JK, Lee J, et al. Histone deacetylaseinhibition by sodium butyrate chemotherapy ameliorates theneurodegenerative phenotype in Huntington's disease mice. J Neurosci 2003; 23: 9418-27.
127. Keene CD, Rodrigues CM, Eich T, et al. Tauroursodeoxycholic acid, a bile acid, is neuroprotective ina transgenic animal model of Huntington's disease. Proc Natl Acad Sci USA 2002; 99: 10671-6.
128. Kim I, Xu W, Reed JC. Cell death and endoplasmic reticulumstress: disease relevance and therapeutic opportunities. Nat Rev Drug Discov 2008; 7: 1013-30.
129. Wei H, Kim SJ, Zhang Z, et al. ER and oxidative stresses arecommon mediators of apoptosis in both neurodegenerativeand non-neurodegenerative lysosomal storage disorders andare alleviated by chemical chaperones. Hum Mol Genet 2008; 17: 469-77.
130. de Almeida SF, Picarote G, Fleming JV, et al. Chemicalchaperones reduce endoplasmic reticulum stress andprevent mutant HFE aggregate formation. J Biol Chem 2007; 282: 27905-12.
131. Ozcan U, Yilmaz E, Ozcan L, et al. Chemical chaperonesreduce ER stress and restore glucose homeostasis in amouse model of type 2 diabetes. Science 2006; 313: 1137-40.
132. Sarkar S, Rubinsztein DC. Huntington's disease: degradationof mutant huntingtin by autophagy. FEBS J 2008; 275: 4263-70.
133. Webb JL, Ravikumar B, Atkins J, Skepper JN, Rubinsztein DC. Alpha-Synuclein is degraded by both autophagy and theproteasome. J Biol Chem 2003; 278: 25009-13.
134. Tanaka M, Machida Y, Niu S, et al. Trehalose alleviatespolyglutamine-mediated pathology in a mouse model of Huntington disease. Nat Med 2004; 10: 148-54.
135. Sarkar S, Perlstein EO, Imarisio S, et al. Small moleculesenhance autophagy and reduce toxicity in Huntington'sdisease models. Nat Chem Biol 2007; 3: 331-8.
136. Sarkar S, Davies JE, Huang Z, Tunnacliffe A, Rubinsztein DC. Trehalose, a novel mTOR-independent autophagyenhancer, accelerates the clearance of mutant huntingtin andalpha-synuclein. J Biol Chem 2007; 282: 5641-52.
137. Rose C, Menzies FM, Renna M, et al. Rilmenidine attenuatestoxicity of polyglutamine expansions in a mouse model of Huntington's disease. Hum Mol Genet 2010; 19: 2144-53.